World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
79
Citations
20619
World Ranking
1702
National Ranking
840

Overview

James W. Hodge is affiliated with the National Institutes of Health in the United States. Their research primarily spans the fields of Medicine and Immunology and Microbiology, with a focus on Oncology and Immunology as subfields. Other areas of study include Pulmonary and Respiratory Medicine, Genetics, and Surgery.

The scientist's work is concentrated on several main topics:

  • Cancer Immunotherapy and Biomarkers
  • Immune Cell Function and Interaction
  • Immunotherapy and Immune Responses
  • CAR-T cell therapy research
  • Immune cells in cancer
  • Sarcoma Diagnosis and Treatment
  • Head and Neck Surgical Oncology

Frequent coauthors collaborating with James W. Hodge include:

  • Kellsye P. Fabian
  • Michelle R. Padget
  • Jeffrey Schlom
  • Clint Allen
  • James L. Gulley

James W. Hodge has published extensively in several venues, with notable numbers of publications in the following journals and proceedings:

  • Journal for ImmunoTherapy of Cancer
  • Regular and Young Investigator Award Abstracts
  • Frontiers in Oncology
  • Cancer Immunology Research
  • Cancers

Selected recent papers by James W. Hodge include:

  • "Consensus guidelines for the definition, detection and interpretation of immunogenic cell death" (2020, Journal for ImmunoTherapy of Cancer)
  • "Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study" (2020, Clinical Cancer Research)
  • "PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations" (2020, Journal for ImmunoTherapy of Cancer)
  • "From Immunogenic Cell Death to Immunogenic Modulation: Select Chemotherapy Regimens Induce a Spectrum of Immune-Enhancing Activities in the Tumor Microenvironment" (2021, Frontiers in Oncology)
  • "The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy" (2021, Molecular Therapy - Oncolytics)

Best Publications

  • Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy

    Eric A. Reits;James W Hodge;Carla A Herberts;Tom A M Groothuis

  • Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

    Lorenzo Galluzzi;Ilio Vitale;Sarah Warren;Sandy Adjemian

  • Consensus guidelines for the detection of immunogenic cell death

    Oliver Kepp;Laura Senovilla;Ilio Vitale;Erika Vacchelli

  • Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes

    Charlie T. Garnett;Claudia Palena;Mala Chakarborty;Kwong-Yok Tsang

  • Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy

    Mala Chakraborty;Scott I. Abrams;Kevin Camphausen;Kebin Liu

  • External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing.

    Mala Chakraborty;Scott I. Abrams;C. Norman Coleman;Kevin Camphausen

  • Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?

    Michael B. Bernstein;Sunil Krishnan;James W. Hodge;Joe Y. Chang

  • Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer

    James L. Gulley;Philip M. Arlen;Anne Bastian;Steven Morin

  • Phase I Study of Sequential Vaccinations With Fowlpox-CEA(6D)-TRICOM Alone and Sequentially With Vaccinia-CEA(6D)-TRICOM, With and Without Granulocyte-Macrophage Colony-Stimulating Factor, in Patients With Carcinoembryonic Antigen–Expressing Carcinomas

    John L. Marshall;James L. Gulley;Philip M. Arlen;Patricia K. Beetham

  • Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death

    Abhishek D. Garg;Lorenzo Galluzzi;Lionel Apetoh;Lionel Apetoh;Thais Baert

  • Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing

    Sofia R. Gameiro;Momodou L. Jammeh;Max M. Wattenberg;Kwong Y. Tsang

  • Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.

    James L. Gulley;Philip M. Arlen;Ravi A. Madan;Kwong-Yok Tsang

  • A triad of costimulatory molecules synergize to amplify T-cell activation.

    James W. Hodge;Helen Sabzevari;Alicia Gómez Yafal;Linda Gritz

  • Chemotherapy‐induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death

    James W. Hodge;Charlie T. Garnett;Benedetto Farsaci;Claudia Palena

  • Combination of Docetaxel and Recombinant Vaccine Enhances T-Cell Responses and Antitumor Activity: Effects of Docetaxel on Immune Enhancement

    Charlie T. Garnett;Jeffrey Schlom;James W. Hodge

  • Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma

    James L. Gulley;Philip M. Arlen;Kwong-Yok Tsang;Junko Yokokawa

  • Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.

    Ravi A Madan;Philip M Arlen;Mahsa Mohebtash;James W Hodge

  • Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses

    James W. Hodge;Joanne P. McLaughlin;Judith A. Kantor;Jeffrey Schlom

  • Induction of Antitumor Immunity by Recombinant Vaccinia Viruses Expressing B7-1 or B7-2 Costimulatory Molecules

    James W. Hodge;Scott Abrams;Jeffrey Schlom;Judy A. Kantor

  • Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study

    Erika J Lampert;Alexandra S Zimmer;Michelle R Padget;Ashley Cimino-Mathews

  • Abstract 632: Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing

    Sofia R. Gameiro;Momodou L. Jammeh;Max M. Wattenberg;Kwong Y. Tsang

Frequent Co-Authors

Jeffrey Schlom
Jeffrey Schlom National Institutes of Health
James L. Gulley
James L. Gulley National Institutes of Health
Kwong Y. Tsang
Kwong Y. Tsang National Institutes of Health
Philip M. Arlen
Philip M. Arlen National Institutes of Health
John W. Greiner
John W. Greiner National Institutes of Health
Seth M. Steinberg
Seth M. Steinberg National Institutes of Health
Massimo Fantini
Massimo Fantini Precision Biologics
Scott I. Abrams
Scott I. Abrams Roswell Park Cancer Institute
Soldano Ferrone
Soldano Ferrone Harvard University
Dennis Panicali
Dennis Panicali Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related online degrees can provide versatile career options in healthcare and research. Many students pivot towards nursing programs, which offer practical applications of immunological principles in patient care.

If you’re new to the field, consider online nursing programs for non nurses. These programs are designed to help individuals without a nursing background quickly enter the profession and build relevant skills.

For faster routes, accelerated nursing programs near me offer intensive coursework that compresses the traditional timeline for earning a Bachelor of Science in Nursing.

There are also options like the best easiest lpn programs to get into, which provide foundational nursing credentials and can be a stepping stone to advanced roles specializing in immunological care.

For those aiming to become advanced practitioners, seeking out the easiest fnp program can ease the path to becoming a Family Nurse Practitioner, where immunology knowledge is essential for managing patients with immune-related conditions.

Best Scientists Citing James W. Hodge

Trending Scientists